BioNTech SE (BVMF:B1NT34)

Brazil flag Brazil · Delayed Price · Currency is BRL
34.25
+1.46 (4.45%)
At close: Apr 27, 2026
-4.97%
Market Cap 128.46B
Revenue (ttm) 18.56B
Net Income (ttm) -7.35B
Shares Out n/a
EPS (ttm) -30.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 651
Average Volume 453
Open 31.89
Previous Close 32.79
Day's Range 31.89 - 34.25
52-Week Range 25.78 - 43.61
Beta 1.59
RSI 68.22
Earnings Date May 5, 2026

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 7,807
Stock Exchange Brazil Stock Exchange
Ticker Symbol B1NT34
Full Company Profile

Financial Performance

In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.

Financial numbers in EUR Financial Statements

News

There is no news available yet.